BioMedNewsBreaks

MondayOct 11, 2021 1:27 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Preparing for Clinical Trials Amid Growing Push for New Federally Approved Therapeutic

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) expects to soon launch a phase 2a clinical trial to determine the efficacy of its psychedelic drug candidate TRP-8802 in treating Prader-Willi Syndrome, hypothalamic obesity eating disorder resulting from removal of a brain tumor, and binge eating disorder. According to a recent article, TRP-8802 will be used in combination with psychotherapy under professional care to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect. Tryp then plans to proceed into phase 2b clinical trials with drug candidate TRP-8803 to test the trademarked product’s ability to penetrate the natural blood-brain…

Continue Reading

MondayOct 11, 2021 9:54 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Berubicin’s Impressive Potential in Syndicated Broadcast

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. According to the update, the audio press release covers CNS Pharmaceuticals’ recent announcement of dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types…

Continue Reading

FridayOct 08, 2021 11:36 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Poised to Become Global Leader in Manufacture of Rare Cannabinoids

InMed Pharmaceuticals (NASDAQ: INM) recently announced it had signed a definitive agreement to acquire 100% of BayMedica Inc., a U.S.-based private company specializing in the manufacture and commercialization of rare cannabinoids. InMed CEO Eric A. Adams described the acquisition as a transformative transaction for the company as it would give InMed a breadth of synthetic cannabinoid manufacturing capabilities. “BayMedica brings unparalleled cannabinoid manufacturing expertise in both chemical synthesis and biosynthesis together with industry veterans who have been pioneers in this space,” a recent article quotes Adams as saying. The article further notes that, once closed, the transaction will create a…

Continue Reading

TuesdayOct 05, 2021 1:04 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Participate at Upcoming LD Micro Main Event

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has announced that it will be featured at the 14th annual LD Micro Main Event conference; the conference will be a virtual event. As part of the company’s presence at the conference, NMRD CEO Faz Chowdhury, PhD, will present an overview of the company. That presentation is scheduled for Oct. 13, 2021, at 10 a.m. ET. To view the full presentation, visit https://ibn.fm/QtCSC To view the full press release, visit https://ibn.fm/KjeJg About Nemaura Medical Inc. Nemaura Medical…

Continue Reading

TuesdayOct 05, 2021 11:55 am

BioMedNewsBreaks – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Featured in Latest Episode of ‘Bell2Bell’ Podcast

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) was featured in the “Bell2Bell Podcast,” a part of IBN’s (“InvestorBrandNetwork”) sustained effort to provide specialized content distribution via widespread syndication channels. Avricore Health’s CEO Hector Bremner joined the latest episode to discuss the company’s business model and its continuing efforts to lead the charge and improve early detection and screening practices throughout the health care industry. “We’re a company focused on diagnostics. We place a system within the pharmacy where a blood test or a molecular test can be done. A simple sample is collected, and the whole test takes about 15 minutes,”…

Continue Reading

MondayOct 04, 2021 10:18 am

BioMedNewsBreaks — Brain Scientific Inc. (BRSF), Piezo Motion Finalize Merger, Announce CEO

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has completed its merger with Piezo Motion Corp., a leading innovator of high-precision motion technology. The merger, which brings together the two teams with an objective of solving challenges using machine learning in the physical and social science markets, had been announced previously. With the merger, which involved Brain Scientific acquiring 100% of Piezo Motion’s outstanding shares, the combined company is expected to expand both its market reach and ability to bring new disruptive products to the market. According to the announcement, Hassan Kotob was named CEO and chair of…

Continue Reading

MondayOct 04, 2021 10:04 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Achieves Several Key Milestones in 2021

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, has so far reached several key milestones in 2021. According to a recent article, these include: “raising $23 million in a bought deal short form prospectus public offering that closed in February this year. On the technology side, MCURF launched the minimum viable product (‘MVP’) of iSTRYM in Q3 2021. On the drug development and research side, the company synthesized ibogaine and has launched the second stage of manufacturing pharmaceutical grade ibogaine to be used in clinical research. The company has also filed…

Continue Reading

MondayOct 04, 2021 9:48 am

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Study Results Confirming Correlation Between CDA Score, Risk of Cancer

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reached a significant milestone and positive result in its general-population, cancer-risk assessment tests and subsequent follow-up study. At the end of September 2021, healthcare providers confirmed more than 2,000 cancer, precancer and disease cases. According to the announcements, those cases include 22 identified types of cancer, 25 identified types of precancer and multiple other related diseases. The company also noted that based on an initial analysis, the confirmed cases strongly correlate to CDA test scores. These…

Continue Reading

FridayOct 01, 2021 2:57 pm

BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) Devices Addressing COVID, Research-Related Challenges in Neurological Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has solved issues related to offering neurological services during COVID. The new surge in the Delta variant highlights two problems in hospitals and the neurological market: staff shortages and contamination. “When it comes to neurological services during COVID, Brain Scientific has solved these issues with its two FDA-cleared EEG technologies — the NeuroCap and NeuroEEG. Easy to administer and disposable (the NeuroCap), these low-cost devices allow staff to provide EEGs at the patient’s bedside,” reads a recent article. Brain Scientific’s NeuroCap is disposable, and both devices…

Continue Reading

FridayOct 01, 2021 11:32 am

BioMedNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) to Host Live Event Highlighting New Potential Treatments for Alcohol Use Disorder, Binge Drinking

Clearmind Medicine (CSE: CMND), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced that it will host Psychedelics for Alcoholism. The live virtual event highlights new potential treatments for alcohol use disorder and binge drinking. Registration is open and free to all for the online event, which is slated to start at 12 p.m. ET/9 a.m. PT on Oct. 20, 2021. The event will feature brief speaker presentations followed by a discussion with a question-and-answer session. The company has curated a panel of scientists, thought…

Continue Reading